Thales Expands Technology Partner Ecosystem to Accelerate Enterprises’ Cloud and Digital Transformation Initiatives
12.8.2020 11:00:00 EEST | Business Wire | Press release
Enterprises can now reduce cyber risk and secure their digital transformation initiatives in new markets including Blockchain, Cloud, DevOps, IoT and Code Signing as Thales unveils an expansion of its data protection ecosystem to more than 300 technology partners.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200812005038/en/
(Photo : Thales)
Through these expanded technology integrations, which now include more than 500 IT products and services, Thales is enabling more organisations to integrate its data encryption, hardware security modules, key management and access management technologies with their existing IT infrastructure and cloud services to protect applications, data and identities. This will empower organisations to implement centralised data protection and access management controls for the whole customer journey.
“The use of the cloud and digital transformation is now the cornerstone of any modern company,” said Sebastien Cano, Senior Vice President for Cloud Protection and Licensing Activities at Thales. “Vitally though, those that are truly leading the way are doing so by integrating security by design into their processes from the start. By integrating our data protection products and services with hundreds of technology partners, we can ensure customers and their sensitive data are protected throughout their entire transformation journey and remain at the forefront of their industries.”
Protecting Blockchain
Thales is collaborating with leading companies that are driving the adoption of Blockchain technology by integrating its Luna Network Hardware Security Modules (HSM) as the root of trust to secure blockchain-based transactions. Recently, Thales integrated its Luna Network HSM with CLS Group – a dedicated crypto processor that is specifically designed for the protection of the crypto key lifecycle – and Hyperledger – a multi-project open source collaborative effort hosted by The Linux Foundation, created to advance cross-industry blockchain technologies.
Enabling Secure Cloud Transformation
Today, organisations on average use 29 cloud services for their collaboration, computing, customer relationship management and storage needs. Thales is helping companies secure the move to the cloud with cloud key management and access management solutions that integrate with the most widely used cloud platforms and services including AWS, Azure, Box, Office365 and Slack.
Thales’s SafeNet Trusted Access enables organisations to modernise their IT and Identity and Access Management (IAM) schemes, as part of their cloud transformation initiatives. For example, integrations with IGA vendors such as SailPoint enable secure identity governance and identity management workflows; Security for privileged users is achieved by securing PAM solutions such as BeyondTrust, at the access point; and continuous authentication and access control is enabled by working with CipherCloud’s CASB solution.
Securing Hybrid IT Environments
While organisations are rapidly adopting cloud services and moving infrastructure to the cloud, the majority are maintaining hybrid IT environments. One of the key challenges they face in doing so is bridging between modern and cloud IAM schemes. To this end, SafeNet Trusted Access’s integration with F5 BIG IP enables enterprises to implement smart SSO for cloud services while securing on premises legacy applications.
“Data and applications are fast becoming the lifeblood of any organisation, no matter the industry,” said John Morgan, VP & GM Security at F5. “For any customer to truly take advantage of this digital transformation, applications and their underlying data must be secure. By joining the Thales partner ecosystem, we are continuing our long history of collaboration to help customers achieve positive business outcomes through secure digital transformation.”
Enabling Trust for DevOps
Digital certificates play an integral role in DevOps workflows, securing authentication across users, devices and applications. The secure identities and certificates establish trust within enterprise infrastructure, pipeline, code and containers. Thales has expanded its DevOps technology partners to include Red Hat, HashiCorp, Kubernetes, VMWare Tanzu, Docker and Google for secure DevOps to enable customers to realise the benefits of automation, scale, & cloud native applications and digital transformation.
Securing the Identities and Data in IoT
In order to secure, manage and authenticate the billions of identities that will be created with the Internet of Things, Thales has recently expanded integrations for its HSMs, Data Encryption and Key Management solutions with leading providers of IoT security solutions such as Cisco, Microsoft, DigiCert, Sectigo, GlobalSign, KeyFactor and Venafi to help organisations secure the billions of identities that will be created over the next few years.
Code Signing becomes an essential service for businesses
Code signing has emerged as an essential ingredient to doing business for virtually any organisation that distributes code to customers and partners. Code signing verifies who the publisher of a specific set of code is and attests that it has not been modified since it was signed. Certificates delivered along with software that has been signed are a key way for users to determine whether software originates from a legitimate source before installing. Today, many software marketplaces, including mobile app stores, require code to be compliant with specific digital signing requirements.
One of those mandates is for applicants to generate and store their private key using a FIPS 140-2 Level 2 certified hardware solution. This can be a Hardware Security Module (HSM) that protects the identity, whether it is the server, virtualization server or the user. Thales' HSMs take the security one step further by storing the signing material in a hardware device, thus ensuring authenticity and integrity of a code file. Thales code signing partners include Adobe, DigiCert, Garantir GlobalSign, Keyfactor, Microsoft and Venafi.
|
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
Thales Group
Market page
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005038/en/
Contact information
PRESS
Thales, Media Relations
Constance Arnoux
+33 (0)6 44 12 16 35
constance.arnoux@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
